An open label, multi-center, phase II study to investigate the safety and efficacy of SDX-101 (R-Etodolac) in patients with relapsed or refractory multiple myeloma (MM).
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2014
At a glance
- Drugs SDX 101 (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Cephalon
- 08 Aug 2006 New trial record.